Literature DB >> 18068916

Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides.

Arwyn T Jones1.   

Abstract

A major goal in drug delivery is to be able to design a macromolecular entity that utilises an endocytic pathway to deliver a bioactive payload into a malfunctioning cell. However, the effectiveness of this approach may be constrained by insufficient information regarding the fate of the delivery vector within the confines of the endo-lysosomal network. Successful drug delivery through this mechanism is therefore dependent on an equal high level of understanding of the specific endocytic pathways that are inherent in the target cell and the traffic and fate of the macromolecule within endocytic organelles. Cell penetrating peptides (CPPs) are promising candidate vectors for delivering macromolecules, however, there is little consensus regarding their exact mechanism of uptake. This review highlights the numerous endocytic pathways and sorting mechanisms that may deliver CPPs to a number of cellular destinations. Our use of non-adherent leukaemia cell lines to study the cellular dynamics of CPPs HIV-TAT and octaarginine is also discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18068916     DOI: 10.1016/j.ijpharm.2007.10.046

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  16 in total

1.  Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8.

Authors:  Catherine L Watkins; Edward J Sayers; Chris Allender; David Barrow; Christopher Fegan; Paul Brennan; Arwyn T Jones
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

Review 2.  The pervasiveness of macropinocytosis in oncological malignancies.

Authors:  Cosimo Commisso
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-04       Impact factor: 6.237

3.  Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Drug Deliv Transl Res       Date:  2012-06-01       Impact factor: 4.617

4.  Cell-penetrating peptides with intracellular actin-remodeling activity in malignant fibroblasts.

Authors:  Diane Delaroche; François-Xavier Cantrelle; Frédéric Subra; Carine Van Heijenoort; Eric Guittet; Chen-Yu Jiao; Laurent Blanchoin; Gérard Chassaing; Solange Lavielle; Christian Auclair; Sandrine Sagan
Journal:  J Biol Chem       Date:  2009-12-27       Impact factor: 5.157

5.  Statistical analysis of nanoparticle dosing in a dynamic cellular system.

Authors:  Huw D Summers; Paul Rees; Mark D Holton; M Rowan Brown; Sally C Chappell; Paul J Smith; Rachel J Errington
Journal:  Nat Nanotechnol       Date:  2011-01-23       Impact factor: 39.213

Review 6.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

7.  Molecular mechanisms in the dramatic enhancement of HIV-1 Tat transduction by cationic liposomes.

Authors:  Guan-Han Li; Wenxue Li; Russell J Mumper; Avindra Nath
Journal:  FASEB J       Date:  2012-03-23       Impact factor: 5.191

Review 8.  Challenges in design and characterization of ligand-targeted drug delivery systems.

Authors:  Silvia Muro
Journal:  J Control Release       Date:  2012-06-15       Impact factor: 9.776

9.  Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting.

Authors:  Maria Ansar; Daniel Serrano; Iason Papademetriou; Tridib Kumar Bhowmick; Silvia Muro
Journal:  ACS Nano       Date:  2013-11-20       Impact factor: 15.881

10.  A DNA-Device that Mediates Selective Endosomal Escape and Intracellular Delivery of Drugs and Biologicals.

Authors:  Silvia Muro
Journal:  Adv Funct Mater       Date:  2014-05-21       Impact factor: 18.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.